Executive Team

1.M. Rami Reddy, Ph.D., --Chairman and Managing Director

Dr. Reddy has wide spectrum of knowledge in the field of drug discovery, and has made significant contributions in his 25-year career. He is one of the few experts in the world in developing novel computational methods and their applications for drug discovery. He was responsible for successfully developing and commercializing a highly accurate Computer-Aided Drug Design (CADD) Technology intended to speed-up drug discovery process. He is currently co-founder and chairman of Rational Labs Inc., San Diego, CA, USA and Rational Labs, Hyderabad, and also a Visiting Professor at the Centre for Modeling, Simulation and Design, Central University of Hyderabad, Hyderabad . Dr. Reddy is the recipient of TANA (USA) 2009 award for excellence in Science and also received a major grant from Department of Science and Technology to further develop his Novel CADD Technical for discovering novel drugs such as Cancer, Diabetes , AIDS, etc by reducing time and costs during drug discovery process.

Dr. Reddy received his Ph.D. in Computational Chemistry from the Central University of Hyderabad in 1983. He held postdoctoral fellowships from 1983 to 1987 at several universities where he studied solvent free energies of small- drug molecules as well as proteins which are related for discovering drugs for AIDS, Cancer and Diabetes using Monte Carlo, molecular dynamics simulations and free energy perturbation methods. From 1988 – 1992, he was a Senior Research Scientist at Pfizer, San Diego. Dr. Reddy’s structure-based drug discovery efforts at Agouron led to several clinical candidates for cancer and one FDA approved drug for AIDS (Viracept). From 1992-2007, he serverd at Gensia Pharmaceuticals, Inc. (now Metabasis Therapeutics, Inc.) in various capacities and finally as an Executive Director, working in the research areas of cardiovascular, pain, cancer, hyperlipidemia, and diabetes using rational drug discovery approaches and his efforts led to several clinical and pre-clinical candidates which are being developed for Cancer, Pain, Type-2 Diabetes, AIDS & Hyperlipidemia. Dr. Reddy’s current research interests are in developing highly accurate novel CADD methods and their application for the discovery of novel drugs by saving significant amount of time and money during drug discovery process for critical human diseases such as diabetes, AIDS and cancer.

Dr. M. Rami Reddy is an author of over 100 scientific publications, many of them are in prestigious Journal of American Chemical Society and Proceeding of National Academy of Sciences, USA. He holds seven patents and is an author of two text books on rational drug design. He is also an author of several novel CADD programs. Dr Reddy has extensively lectured all over the world in the field. He is an Executive Editor of Current Pharmaceutical Design. He has organized seven symposiums on computational aspects of Rational Drug Design and Structure Based Drug Design at various American Chemical society National meetings (1998-2012).


2. Duvvuri Subrahmanyam, Ph.D. -- President

Dr. Subrahmanyam has received his Ph. D in synthetic organic chemistry in 1989, from Central University of Hyderabad Hyderabad, AP, India under the supervision of Prof. Goverdhan Mehtha, and did his Post-doctroal work at Chemistry department, Michingan State Univ.,East Lansing, MI, USA from 1989-1991 and University of Pensylvania , Philadelphia, PA, USA from 1991- 1993. Dr. Subrahmanyam work during post-doc is related to syntjhesis of novel biological actity compounds related to Natrual products and synthetic Taxol derivatives.. In 1993 he returned to India and joined as Sr. Sceintist , Discovery Medicinal Chemistry Division of Dr. Reddy Research Foundation( DRF) in Hyderabad. and he worked for 7 years till 2000,in the research areas of Cancer & Anti-infectives and also worked in camptothecin, Taxol and podophyllotoxin natural product analogs and synthesized several NCEs and filed patents in USA and Europe. Two new molecules were filed as INDs in cancer in India and have progressed to Ph-II clicnical trials in India.

Dr. Subrahmanyam left DRF in 2000 as Associate Director and joined as General Manager in Chemical Research department of Medicinal chemistry group in Glenmark Researh centre in Navi Mumbai, Mumbai, India. He worked in anti-asthma products and synthesized new compds as PDE-4 inhibitors. And filed patent in USA for this research and 2 of the molecules reached Ph-2 studies in abroad.

In 2002, Dr. Subrahmanyam joined as Head of Medicianl chemistry in GVK BioSciences pvt ltd.,a CRO company in Hyderabad, India. He worked with several multi-national pharma & biotech companies in USA, Europe, Japan, Germany in their FTE programs and synthesized several kinds of molecules for various therapeutic areas. he developed efficient ways of synthesizing focused libraries ( 25-100 compounds) . He lead the large groups of chemists / Sr. Scientists totaling around 300 chemsits & 20 group leaders. H left GVK Bio as Sr Vice president in 2007 and joined 2 other CRO Companies; AVRA labs & Laxai Avanthi pvt ltd., in Hyderabad and worked for 2 years before he joined in Rational Labs.

Dr. Subrahmanyam is an author of about 16 scientific Intl.’ publications, and 7 US patents. And gained expertise in desigining and developing NCEs in Cancer and anti-biotic research. I also gained good exposure to diabetes and related disease areas.


3. Prasad Sunkara, Ph.D. Chief Scientific and Business Advisor

Dr. Sunkara is a leader and serial entrepreneur in the biotechnology, pharmaceutical and medical device industry for more than 35 years. He combines his years of corporate, financing, research, development and management experience in cancer, cardiovascular and CNS disease indications at Marion Merrell Dow pharmaceuticals (now Sanofi Aventis) and nine successful start- up biotech companies in California and Michigan. He is an expert in identifying and licensing compelling technologies from universities and accelerating their preclinical and clinical development on a virtual basis (while minimizing costs) in US and India. Dr. Sunkara also gained valuable experience in business development, financing, mergers and acquisitions as an officer in four and as a founder and CEO of four other start-up biotech companies. He helped them to grow and exit with significant appreciations to shareholders. He was the past president and CEO of Everist genomics, Inc., a personalized medicine company located in Ann Arbor, Michigan, that he helped to grow during a period of two years from a valuation of $10 million to $60 million. He was also a founding Partner and Senior Managing Director at Northstar, a boutique investment bank formed by a group of successful and experienced life science executives with experience in building companies, business development and financing. He has been a chairperson & speaker at international and national conferences, co- inventor on 35 US patents & co-author of 140 scientific articles & book chapters.

Currently, Dr. Sunkara is the President and Chief Executive Officer of Innova Therapeutics, Inc., focusing on commercializing the novel medical devices and products in US, Indian sub-continent and Middle East.


4. B. Padmanabhan, Ph. D. Vice President of Biological Sciences and Structural Biology

Dr. Padmanabhan received his Ph. D in Biophysics & Biochemistry in 1994, from All India Institute of Medical Sciences (AIIMS), New Delhi, India. From 1995 – 1998, he worked as Research Associate in the Pharmaceutical division of Mitsubishi Chemical Corporation (MCC), Yokohama, Japan. At MCC, he worked on few therapeutic targets such as cyotokines, kinases, and -lactamasesto design inhibitor molecules by X-ray crystallography approach. In the Horikoshi Gene Sector Project, ERATO-JST, Tskuba, Japan, from 1999-2002, he worked as Researcher. In this ERATO-JST project, he established a complete structural biology facility and trained the molecular biologists in protein crystallography. he got interest to understand the molecular mechanism of chromatin regulators such as TAF1 interactors, HATs, HDACs, etc.

From 2003 – 2006, Dr. Padmanabhan worked as Senior Scientist & Research Unit Leader in the RIKEN Structural Genomic Initiative (RSGI) at RIKEN Genomic Sciences Center, Yokohama, Japan. and led the team comprised of molecular biologists, cell biologists, protein biochemists and protein crystallographers. Dr. Padmanabhan team had been mainly focused on chromatin regulators/ epigenetics, cell-cycle regulators, signal transduction and environmental stress factors associate with various types of cancers, through structural biology approach. In the chromatin regulators & epigenetics field, his team worked on BET family proteins (BRD2 and BRD4) and its complexes with histones H3 and H4, class I HDACs, histone chaperone Asf1 and its complexes, various TAF1 associate factors and NuRD complex. In the cell-cycle field, he worked on gankyrin complexes in the pRb-CDK4/6 – proteasome degradation pathway, and p53-MDM2-proteasome degradation pathway. In the signal transduction area, he attempted to understand the molecular mechanism of pygopus in the Wnt/ - catenin signaling pathway. He also worked on the Nrf2-Keap1 signaling pathway which plays critical role in the phase II defence system.

From 2007-2009, Dr. Padmanabhan worked as Senior General Manager and Head of Biological Sciences, Aptuit Laurus Pvt. Ltd., Hyderabad, India. At Aptuit Laurus, using structure based drug design approaches, they have discovered several preclinical candidates for cancer and diabetes. Before joined Rational Labs, he briefly worked for BioGenex Pvt. Ltd., Hyderabad, India as Director and Head of Research and Development.

Dr. Padmanabhan is an author of about 40 scientific publications, and 50 Protein Databank entries in the RSCB. he have made numerous invited presentations.